We develop exceptional, innovative biopharmaceuticals
to improve the lives of patients suffering
from serious diseases.
Find out more about MorphoSys.
MorphoSys's vision
13/01/2020
MorphoSys and Incyte Sign Global Collaboration and License Agreement for...
13/01/2020
MorphoSys AG: Ad hoc: MorphoSys and Incyte Sign Global Collaboration and...
30/12/2019
MorphoSys Announces Submission of Biologics License Application for...
27/12/2019
First Patient Dosed in Phase 1 Clinical Study of Tafasitamab in Firstline...
20/11/2019
Markus Enzelberger, Chief Scientific Officer of MorphoSys, Announces His...
18/11/2019
Ad hoc: MorphoSys' tafasitamab B-MIND DLBCL study successfully passed...
15/11/2019
MorphoSys Continues to Build Commercial Presence by Opening new U.S....
